VERAXA Biotech AG (NASDAQ: VRXA) has begun cell line development for its lead BiTAC(R) T-cell engager (BiTAC-TCE) program, marking another step in preparing the company's most advanced oncology candidate for future clinical development. The company announced that it has selected ATUM, a U.S.-based contract research organization specializing in bioengineering and cell line development, to generate stable clonal cell lines using its proprietary Leap-In Transposase(R) technology.
According to VERAXA, the collaboration is intended to support manufacturing, analytical development, and nonclinical studies required before clinical testing. The partnership represents an important development milestone as the candidate advances toward IND/CTA-enabling studies. VERAXA's BiTAC platform is designed to improve the selectivity of T-cell engagers, potentially reducing toxicity associated with conventional approaches.
The company recently expanded its research facilities in Heidelberg, Germany, increasing laboratory capacity as multiple oncology programs move toward clinical development. The selection of ATUM for cell line development leverages their expertise in bioengineering to generate high-producing, stable cell lines critical for producing the therapeutic candidate at scale.
This advancement comes as VERAXA, an emerging leader in designing novel cancer therapies, continues to progress its pipeline. The BiTAC-TCE program is the company's most advanced oncology candidate, and the cell line development partnership is a key step toward initiating clinical trials. For more information, visit the company's newsroom at https://ibn.fm/VRXA.
